UK looks to expand obesity-drug access with pilot program
The UK is looking into making obesity drugs more widely available, as a new class of medicines shows potential for easing the burden of weight-related diseases on the healthcare system.
By Suzi Ring / Bloomberg News
A two-year GBP 40m (USD 49.6m) pilot program will assess how obesity drugs such as Novo Nordisk A/S’s Wegovy can be made more accessible to communities by expanding weight-management services outside of hospitals, the government said Tuesday in a statement.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
